{
    "clinical_study": {
        "@rank": "125974", 
        "arm_group": [
            {
                "arm_group_label": "Rilotumumab Monotherapy", 
                "arm_group_type": "Experimental", 
                "description": "Cohort 1A:  Rilotumumab 10 mg/kg IV Q2W Cohort 1B:  Rilotumumab 20 mg/kg IV Q2W Cohort 1C (if needed):  Rilotumumab 15 mg/kg IV Q2W"
            }, 
            {
                "arm_group_label": "Rilotumumab plus CX", 
                "arm_group_type": "Experimental", 
                "description": "Cohort 2A: Rilotumumab 15 mg/kg IV Day 1 Q3W Cisplatin 80 mg/m2 IV (max of 6 cycles) Day 1 Q3W Capecitabine 1000 mg/m2 PO BID, Days 2-14 Q3W Cohort 2B (if needed): Rilotumumab 10 mg/kg IV Day 1 Q3W Cisplatin 80 mg/m2 IV (max of 6 cycles) Day 1 Q3W Capecitabine 1000 mg/m2 PO BID, Days 2-14 Q3W"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open label phase 1/1b study of Rilotumumab in Japanese subjects with advanced\n      solid tumors or metastatic gastric esphagogastric (GEJ) adenocarcinoma."
        }, 
        "brief_title": "Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Part 1- Advanced Solid Tumors", 
            "Part 2- Advanced or Metastatic Gastric Cancer", 
            "Part 2- Advanced or Metastatic GEJ"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Stomach Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Japanese subjects with pathologically confirmed unresectable locally advanced or\n             metastatic carcinoma which is refractory to standard therapies or for which there is\n             no standard therapy (Part 1 only)\n\n          -  Japanese subjects with pathologically confirmed MET-positive (fulfilling the MET IHC\n             criteria as defined by validated IVD [in vitro diagnostic]) unresectable locally\n             advanced or metastatic gastric or GEJ adenocarcinoma (Part 2 only)\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (0 or 1)\n\n          -  Availability of archival tumor tissue (Part 2 only)\n\n          -  Evaluable (measurable or non-measurable) disease by RECIST 1.1 criteria\n\n          -  Able to tolerate infusions and take oral medications (Part 2 only)\n\n        Key Exclusion Criteria:\n\n          -  Previous systemic therapy (including chemotherapy, biologic, immunotherapy, or\n             investigational therapy) for locally advanced or metstatic gastric or GEJ\n             adenocarcinoma (Part 2 only)\n\n          -  Less than 6 months have elapsed from completion of prior neoadjuvant or adjuvant\n             chemotherapy or chemotherapy to enrollment (Part 2 only)\n\n          -  Squamos cell history (Part 2 only)\n\n          -  Known HER2-overexpressing unresectable locally advanced or metastatic gastric or GEJ\n             adenocarcinoma (Part 2 only)\n\n          -  Resectable disease or suitable for definitive chemoradiation\n\n          -  Subjects who have persistent gastric outlet obstruction, complete dysphagia or are\n             dependent upon jejunostomy for feeding (Part 2 only)\n\n          -  Known central nervous system metastases"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "21", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01791374", 
            "org_study_id": "20110251", 
            "secondary_id": "20110251"
        }, 
        "intervention": [
            {
                "arm_group_label": "Rilotumumab Monotherapy", 
                "description": "Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells.", 
                "intervention_name": "Rilotumumab", 
                "intervention_type": "Drug", 
                "other_name": "AMG 102"
            }, 
            {
                "arm_group_label": "Rilotumumab plus CX", 
                "description": "Drug: Rilotumumab Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells. Drug: Cisplatin A platinum containing chemo-therapy compound that reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death). Drug: Capecitabine A chemo-therapy prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.", 
                "intervention_name": "Rilotumumab", 
                "intervention_type": "Drug", 
                "other_name": "AMG 102"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antibodies, Monoclonal"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Advanced Solid Tumors", 
            "Advanced or Metastatic Gastric Cancer", 
            "Advanced or Metastatic GEJ", 
            "Gastric Cancer"
        ], 
        "lastchanged_date": "December 12, 2013", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Nagoya-shi", 
                        "country": "Japan", 
                        "state": "Aichi", 
                        "zip": "464-8681"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kashiwa-shi", 
                        "country": "Japan", 
                        "state": "Chiba", 
                        "zip": "277-8577"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Matsuyama-shi", 
                        "country": "Japan", 
                        "state": "Ehime", 
                        "zip": "791-0280"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sapporo-shi", 
                        "country": "Japan", 
                        "state": "Hokkaido", 
                        "zip": "060-8648"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kawasaki-shi", 
                        "country": "Japan", 
                        "state": "Kanagawa", 
                        "zip": "216-8511"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kitaadachi-gun", 
                        "country": "Japan", 
                        "state": "Saitama", 
                        "zip": "362-0806"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suntou-gun", 
                        "country": "Japan", 
                        "state": "Shizuoka", 
                        "zip": "411-8777"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Phase 1/1b, Open Label Study Evaluating the Safety, Tolerability and Pharmacokinetics of Rilotumumab in Japanese Subjects", 
        "overall_contact": {
            "last_name": "Amgen Call Center", 
            "phone": "866-572-6436"
        }, 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Japan: Pharmaceuticals and Medical Devices Agency", 
                "Japan: Ministry of Health, Labor and Welfare"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "DLTs are defined as grade 3 or higher adverse events that are related to rilotumumab during the first cycle of therapy. This does not include specific toxicities (eg nausea and vomiting) that are common in cancer patients unless specific criteria are met.", 
                "measure": "Part1: Dose-limiting toxicities (DLT) for each dose level of rilotumumab tested", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }, 
            {
                "description": "DLTs are defined as grade 3 or higher adverse events that are related to rilotumumab or the combination of rilotumumab and CX during the first cycle of therapy. This does not include specific toxicities (eg nausea and vomiting) that are common in cancer patients unless specific criteria are met.", 
                "measure": "Part 2: Dose-limiting toxicities (DLT) for each dose level of rilotumumab in combination with cisplatin and capecitabine (CX) chemotherapy tested", 
                "safety_issue": "Yes", 
                "time_frame": "21 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01791374"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "AEs and laboratory abnormalities are reported by CTCAE (version 3.0) criteria", 
                "measure": "Part 1: Incidence of AEs, clinical laboratory abnormalities and anti-rilotumumab antibodies.", 
                "safety_issue": "Yes", 
                "time_frame": "4 months average"
            }, 
            {
                "measure": "Part 1: Pharmacokinetics parameters of rilotumumab monotherapy as measured by: Maximum concentration, time to achieve maximum concentration, observed minimum concentration, area under the concentration-time curve, terminal elimination half-life.", 
                "safety_issue": "Yes", 
                "time_frame": "4 months average"
            }, 
            {
                "measure": "Part 1: Evaluate efficacy based on the treatment effects of rilotumumab monotherapy as measured by the following: Objective Response Rate, duration of response, progression-free survival.", 
                "safety_issue": "No", 
                "time_frame": "4 months average"
            }, 
            {
                "description": "AEs and laboratory abnormalities are reported by CTCAE (version 3.0) criteria", 
                "measure": "Part 2: Incidence of AEs, clinical laboratory abnormalities and anti-rilotumumab antibodies not defined as DLTs.", 
                "safety_issue": "Yes", 
                "time_frame": "7 months average"
            }, 
            {
                "measure": "Part 2: Pharmacokinetics parameters of rilotumumab in combination with cisplatin and capecitabine as measured by: Maximum concentration, observed minimum concentration, area under the concentration-time curve.", 
                "safety_issue": "Yes", 
                "time_frame": "7 months average"
            }, 
            {
                "measure": "Part 2: Evaluate efficacy based on the treatment effects of rilotumumab in combination with cisplatin and capecitabine as measured by the following: Objective Response Rate, duration of response, progression-free survival, overall survival.", 
                "safety_issue": "No", 
                "time_frame": "7 months average"
            }
        ], 
        "source": "Amgen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}